1. Home
  2. XELB vs XCUR Comparison

XELB vs XCUR Comparison

Compare XELB & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xcel Brands Inc.

XELB

Xcel Brands Inc.

N/A

Current Price

$0.91

Market Cap

8.4M

Sector

Miscellaneous

ML Signal

N/A

Logo Exicure Inc.

XCUR

Exicure Inc.

N/A

Current Price

$1.31

Market Cap

9.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XELB
XCUR
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4M
9.2M
IPO Year
2011
2017

Fundamental Metrics

Financial Performance
Metric
XELB
XCUR
Price
$0.91
$1.31
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
110.0K
38.9K
Earning Date
04-07-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
48.37
83.37
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$102.11
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$1.05
52 Week High
$2.66
$9.48

Technical Indicators

Market Signals
Indicator
XELB
XCUR
Relative Strength Index (RSI) 40.76 43.22
Support Level $0.63 $1.20
Resistance Level $1.16 $1.48
Average True Range (ATR) 0.08 0.11
MACD 0.02 0.03
Stochastic Oscillator 13.34 23.17

Price Performance

Historical Comparison
XELB
XCUR

About XELB Xcel Brands Inc.

Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: